Clinical Trials by Tumor Biology & Microbiology Program Members

Dr. Vaishampayan is conducting a pilot trial of oral cabozantinib/ XL184 in metastatic castrate resistant prostate cancer to explore the changes in bone and tumor imaging related pathways (KCI Protocol # 2011-185). It is now closed to accrual, but research related intervention and follow up are ongoing.

In collaboration with Dr. Gadgeel (MT), Dr. Hillman studies the effects of soy isoflavones on decreasing or preventing the inflammation associated with lung cancer radiation therapy (Hillman G, J Thorac Oncol, 2013). Based on this study, there is a PI-initiated clinical trial of Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients with Stage IIIA-IIIB Non-Small Cell Lung Cancer (KCI protocol #2013-021).

Drs. Vaishampayan and Heath (MT) are co-investigators on a multi-institutional study to evaluate immune responses to Sipuleucel-T in African American men and non-African American men with castrate resistant prostate cancer (Protocol #2013-108) which is a multi-center grant involving the Prostate Cancer Clinical Trials consortium [(Barbara Ann Karmanos Cancer Center (Wayne State University), Carbone Cancer Center (University of Wisconsin), Dana-Farber Cancer Institute (Harvard Medical School), Duke Cancer Institute, Fred Hutchinson Cancer Research Center (University of Washington), Helen Diller Family Comprehensive Cancer Center (University of California San Francisco), Knight Cancer Institute (Oregon Health and Science University), MD Anderson Cancer Center (University of Texas), Memorial Sloan Kettering Cancer Center, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins University), University of Chicago Comprehensive Cancer Center, University of Medicine and Dentistry of New Jersey, and Henry Ford Health System.